Skip to main content
SpringerLink
Log in

Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT™) in attention-deficit hyperactivity disorder in children aged 6–17 years: a profile of their use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The extended-release orally disintegrating tablet (XR-ODT) formulation of methylphenidate (Cotempla XR-ODT™) is an effective and generally well-tolerated option for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Because of the pharmacokinetic profile of this formulation, methylphenidate XR-ODT is administered once daily. As methylphenidate XR-ODT comprise both immediate- and extended-release methylphenidate particles, its use may be of particular benefit in individuals who require a rapid onset (clinical improvements are shown within 1 h) and prolonged reduction in ADHD symptoms (clinical improvements are maintained for 12 h). The XR-ODT formulation of methylphenidate allows relatively easy administration (the ODT dissolves rapidly on the tongue, followed by swallowing of the disintegrated particles with saliva without the need for water), which may be of particular benefit in children and adolescents who have difficulty swallowing tablets or capsules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.

    Article  PubMed Central  Google Scholar 

  2. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209–25.

    Article  PubMed  Google Scholar 

  3. Cortese S, D’Acunto G, Konofal E, et al. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2017;31(2):149–60.

    Article  PubMed  Google Scholar 

  4. Mattingly GW, Wilson J, Rostain AL. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657–66.

    Article  PubMed  Google Scholar 

  5. Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII: US prescribing information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.

  6. Prince J. Catecholamine dysfunction in attention-deficit/ hyperactivity disorder: an update. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S39–45.

    Article  CAS  PubMed  Google Scholar 

  7. Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008;28(3 Suppl 2):S54–61.

    Article  CAS  PubMed  Google Scholar 

  8. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S46–53.

    Article  CAS  PubMed  Google Scholar 

  9. Quinn D. Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S62–6.

    Article  PubMed  Google Scholar 

  10. Markowitz JS, DeVane CL, Pestreich LK, et al. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006;16(6):687–98.

    Article  PubMed  Google Scholar 

  11. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997;131(1):71–8.

    Article  CAS  PubMed  Google Scholar 

  12. Childress A, Newcorn J, Stark JG, et al. A single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26(6):505–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Weisler RH, Stark JG, Sikes C. Fed and fasted administration of a novel extended-release methylphenidate orally disintegrating tablet formulation for the treatment of ADHD. Clin Pharmacol Drug Develop. 2017. https://doi.org/10.1002/cpdd.361.2017 (Epub).

    Google Scholar 

  14. Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43(6):1084–95.

    Article  CAS  PubMed  Google Scholar 

  16. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: A.C. Childress, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA. During the peer review process, the manufacturer of methylphenidate XR-ODT was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest. Additional information about this Adis Drug Review can be found http://www.medengine.com/Redeem/3DCCF0606350342C.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT™) in attention-deficit hyperactivity disorder in children aged 6–17 years: a profile of their use. Drugs Ther Perspect 34, 43–49 (2018). https://doi.org/10.1007/s40267-017-0462-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-017-0462-2

Search

Navigation